PHILADELPHIA — The Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania, has awarded its inaugural grants funded by proceeds from the 2014 Million Dollar Bike Ride. Thirteen institutions – from academia in the US, Canada, Germany, and Australia – received grants ranging from $35,000 to $60,000 from funds raised by 13 disease-specific cycling teams.
Orphan diseases represent a collection of disorders that afflict less than 200,000 individuals for any single disease type. Despite their rarity in the population, there are more than 7,000 distinct orphan diseases. In all, over 25 million people in the United States suffer from complications associated with from orphan diseases; thousands die from them each year. Despite this toll, research in most disease types has lagged far behind other major areas due to a combination of technological and funding limitations.
The Million Dollar Bike Ride does not benefit just one rare disease, but many. Individual cyclists register and raise money for their specific orphan/rare disease foundation. Funds raised support pilot research projects and investigators studying a specific rare disease. These awards were made through a competitive call for proposals related to the needs of the individual disease foundations and reviewed by experts in each disease area.
The awards:
Team ALD (Adrenoleukodystrophy)
Florian Eichler, MD
Massachusetts General Hospital / Harvard Medical School
Pilot study on adeno-associated virus serotype 9-mediated gene therapy for adrenomyeloneuropathy
Team CHI (Congenital Hyperinsulinism)
Diva De Leon, MD, MSCE
Children's Hospital of Philadelphia
Pilot study of the efficacy and safety of sirolimus in the treatment of congenital hyperinsulinism
Team Cure CMD (Congenital Muscular Dystrophy)
Pam Van Ry, PhD
University of Nevada School of Medicine
Postdoctoral fellowship to study galectin-1 protein therapy for the treatment for laminin alpha2 related congenital muscular dystrophy
Team FH (Familial Hypercholesterolemia)
Chutikarn Butkinaree, PhD
Clinical Research Institute of Montreal, Canada
Postdoctoral fellowship to study the molecular mechanisms of PCSK9-induced LDLR degradation
Team FARA (Friedreich’s Ataxia Research Alliance)
Yogesh Chutake, PhD
University of Oklahoma HSC
Postdoctoral fellowship Reversal of epigenetic promoter silencing in Friedreich ataxia by histone deacetylase inhibitors
Team Spin Factor for Hemophilia
Oscar Marcos-Contreras, PhD
The Children's Hospital of Philadelphia
Hemophilia Postdoctoral fellowship for $35,000
Enhancing coagulation factor expression in skeletal muscle by augmenting the endogenous post-translational protein modification machinery: application to hemophilia gene therapy
Team LAM (Lymphangioleiomyomatosis)
Aristotelis Astreinidis, PhD
Texas Tech University Health Sciences Center
Pilot study to evaluate PLK1 inhibitors in a pre-clinical LAM animal model
Vera Krymskaya, PhD, MBA
University of Pennsylvania
Pilot study of STAT3 in pulmonary lymphangioleiomyomatosis (LAM)
Team ML4 (Mucolipidosis type 4)
Susan Slaugenhaupt, PhD
Massachusetts General Hospital
Pilot study to study targeting miR-155 as a therapy for mucolipidosis IV
Team MPS (Mucopolysaccharidosis)
Alena Svatkova, MD
University of Minnesota
Postdoctoral fellowship to unravel the basis of white matter disease in mucopolysaccharidosis type I – a DTI study
Team NPC (Niemann Pick type C)
Ashley Bush, MB BS, DPM, FRANZCP, PhD, FTSE, NHMRC Australia Fellow
The Florey Institute of Neuroscience and Mental Health, Australia
Pilot study of dual targeting of defective lipid and metal pathways in Niemann-Pick type C disease: an in vitro pilot study
Brittney Gurda, PhD
University of Pennsylvania, School of Veterinary Medicine
Postdoctoral fellowship to study CNS gene therapy to restore NPC1 protein expression in cerebellar Purkinje cells and delay or prevent disease onset in feline Niemann-Pick type C1 (NPC1) disease
Team Pitt Hopkins Pedalers
Daniel Marenda, PhD
Drexel University
Pilot study to understand TCF4 function in post-mitotic neuron synaptic plasticity
Benjamin Philpot, PhD
University of North Carolina, Chapel Hill
Pilot study to identify molecular targets for Pitt-Hopkins Syndrome treatments
Team RASopathies
Maria Kontaridis, PhD
Beth Israel Deaconess Medical Center/Harvard Medical School
Pilot study to delineate the cause of gastrointestinal abnormalities in RASopathy disorders using human inducible pluripotent stem cells (iPSCs)
Team NTSAD (National Tay-Sachs and Allied Diseases Association)
Annette Bley, MD
University Medical Center Hamburg-Eppendorf, Germany
Postdoctoral fellowship to quantitatively describe the clinical course of Canavan disease
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.